Related Experiment Video
Updated: Mar 10, 2026

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
TET1 Depletion Induces Aberrant CpG Methylation in Colorectal Cancer Cells
Masahiro Kai1, Takeshi Niinuma1, Hiroshi Kitajima1
1Department of Molecular Biology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Abstract:
Aberrant DNA methylation is commonly observed in colorectal cancer (CRC), but the underlying mechanism is not fully understood. 5-hydroxymethylcytosine levels and TET1 expression are both reduced in CRC, while epigenetic silencing of TET1 is reportedly associated with the CpG island methylator phenotype. In the present study, we aimed to clarify the relationship between loss of TET1 and aberrant DNA methylation in CRC. Stable TET1 knockdown clones were established using Colo320DM cells, which express high levels of TET1, and HCT116 cells, which express TET1 at a level similar to that in normal colonic tissue. Infinium HumanMethylation450 BeadChip assays revealed increased levels of 5-methylcytosine at more than 10,000 CpG sites in TET1-depleted Colo320DM cells. Changes in DNA methylation were observed at various positions within the genome, including promoters, gene bodies and intergenic regions, and the altered methylation affected expression of a subset of genes. By contrast, TET1 knockdown did not significantly affect DNA methylation in HCT116 cells. However, TET1 depletion was associated with attenuated effects of 5-aza-2'-deoxycytidine on gene expression profiles in both cell lines. These results suggest that loss of TET1 may induce aberrant DNA methylation and may attenuate the effect of 5-aza-2'-deoxycytidine in CRC cells.
Insights
Loss of TET1 enzyme in colorectal cancer (CRC) cells leads to widespread DNA methylation changes. This TET1 depletion also reduces the effectiveness of epigenetic drugs, impacting CRC treatment strategies.
Area of Science:
- Epigenetics
- Cancer Biology
- Molecular Oncology
Background:
- Aberrant DNA methylation is a hallmark of colorectal cancer (CRC), but its mechanisms remain unclear.
- Reduced 5-hydroxymethylcytosine and TET1 expression are observed in CRC.
- Epigenetic silencing of TET1 is linked to the CpG island methylator phenotype in CRC.
Purpose of the Study:
- To investigate the relationship between TET1 loss and aberrant DNA methylation in colorectal cancer.
- To determine the functional consequences of TET1 depletion on DNA methylation patterns and gene expression in CRC cells.
Main Methods:
- Stable TET1 knockdown was established in Colo320DM (high TET1) and HCT116 (normal TET1 levels) CRC cell lines.
- Infinium HumanMethylation450 BeadChip assays were employed to analyze genome-wide DNA methylation.
- Gene expression profiles were assessed following TET1 depletion and treatment with 5-aza-2'-deoxycytidine.
Main Results:
- TET1 depletion in Colo320DM cells caused significant increases in 5-methylcytosine at over 10,000 CpG sites, affecting promoters, gene bodies, and intergenic regions.
- Altered DNA methylation in TET1-depleted cells impacted the expression of a subset of genes.
- TET1 knockdown did not significantly alter DNA methylation in HCT116 cells but attenuated the gene expression effects of 5-aza-2'-deoxycytidine in both cell lines.
Conclusions:
- Loss of TET1 function may contribute to aberrant DNA methylation patterns observed in colorectal cancer.
- TET1 depletion can reduce the efficacy of DNA methyltransferase inhibitors like 5-aza-2'-deoxycytidine in CRC cells.
- These findings highlight TET1's role in maintaining DNA methylation homeostasis and its potential as a therapeutic target in CRC.
Related Concept Videos
Abnormal Proliferation
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

